Brief Description
Vedere Bio II is pioneering beyond traditional gene therapy to not just slow vision loss from inherited retinal degenerations (IRDs) or dry age-related macular degeneration (dry AMD) with geographic atrophy (GA), but actually restore it.
Timeline
- 2021. Vedere Bio II launches as the successor to the first Vedere Bio, which was acquired by Novartis in September 2020
Inventors
Matthew Banghart, Michael Hayden Berry, Katherine Borges, Johannes Broichhagen, John Flannery, Doris Fortin, Benjamin Gaub, Scott Franklin Geller, Pablo Gorostiza, Karen Isabelle Guerin, Amy Holt, Ehud Isacoff, Richard Kramer, Joshua Levitz, Katharine Munckton, Autoosa Salari, Dirk Trauner, Meike Visel, Matthew Volgraf